Hambrecht & Quist Capital Management »

Zentalis Pharmaceuticals shares owned by Hambrecht & Quist Capital Management

Quarter-by-quarter ownership of Zentalis Pharmaceuticals (ZNTL) shares owned by Hambrecht & Quist Capital Management from 13F filings

Historical chart of Hambrecht & Quist Capital Management investment in Zentalis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Zentalis Pharmaceuticals held by Hambrecht & Quist Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Zentalis Pharmaceuticals by Hambrecht & Quist Capital Management

Quarter filed Position value Share count Share price at filing
2023-06-30 $1.1M 40k 28.21

More positions owned by Hambrecht & Quist Capital Management

Amgen Common (AMGN)
Johnson & Johnson Common (JNJ)
Gilead Sciences Common (GILD)
Regeneron Pharmaceuticals Common (REGN)
Vertex Pharmaceuticals Common (VRTX)
Eli Lilly and Company Common (LLY)
Unitedhealth Group Common (UNH)
Merck & Co Common (MRK)
AbbVie Common (ABBV)
Biogen Common (BIIB)
AstraZeneca Sponsored ADR (AZN)
Illumina Common (ILMN)
Abbott Laboratories Common (ABT)
Pfizer Common (PFE)
Thermo Fisher Scientific Common (TMO)

View all positions for Hambrecht & Quist Capital Management

Top funds holding Zentalis Pharmaceuticals

Eventide Asset Management
Vanguard Group
Citadel Advisors
T. Rowe Price Associates
Federated Investors
Decheng Capital
PRIMECAP Management Company
Dimensional Fund Advisors
Bank of America Corporation
Logos Global Management
5AM Venture Management
Caption Management
Boxer Capital
Charles Schwab Investment Management
Paradigm Biocapital Advisors

View all funds holding Zentalis Pharmaceuticals